Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Next Previous
Trial Profile

An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate/niraparib (Primary) ; Prednisone (Primary) ; Abiraterone acetate; Niraparib
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development

Most Recent Events

  • 11 Apr 2023 Planned End Date changed from 6 Dec 2023 to 5 Dec 2025.
  • 30 Dec 2021 Status changed from recruiting to active, no longer recruiting.
  • 02 Dec 2021 Planned End Date changed from 22 Apr 2024 to 6 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top